Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ebiom.2020.102822 http://scihub22266oqcxt.onion/10.1016/j.ebiom.2020.102822 32535547!7286830!32535547     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32535547&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       EBioMedicine 2020 ; 56 (ä): 102822 Nephropedia Template TP {{tp|p=32535547|t=2020. Merits and culprits of immunotherapies for neurological diseases in times of COVID-19 |pdf=|usr=}}{{32535547}} gab.com Text Merits and culprits of immunotherapies for neurological diseases in times of COVID-19 JO: EBioMedicine http://www.kidney.de/pget.php?&tw=1&pmid=32535547 #FOAvip Immunosuppression and immunomodulation are valuable therapeutic approaches for managing neuroimmunological diseases. In times of the Coronavirus disease 2019 (COVID-19) pandemic, clinicians must deal with the question of whether immunotherapy should currently be initiated or discontinued in neurological patients. Uncertainty exists especially because different national medical associations publish different recommendations on the extent to which immunotherapies must be continued, monitored, or possibly switched during the current pandemic. Based on the most recently available data both about the novel coronavirus and the approved immunotherapies for neurological diseases, we provide an updated overview that includes current treatment strategies and the associated COVID-19 risk, but also the potential of immunotherapies to treat COVID-19. Twit Text FOAVip Merits and culprits of immunotherapies for neurological diseases in times of COVID-19 ????EBioMedicine http://www.kidney.de/pget.php?&tw=1&pmid=32535547 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32535547 #FOAvip English Wikipedia <ref>{{Cite pmid|32535547}}</ref> Merits and culprits of immunotherapies for neurological diseases in times of COVID-19 #MMPMID32535547 Pawlitzki M; Zettl UK; Ruck T; Rolfes L; Hartung HP; Meuth SG EBioMedicine 2020[Jun]; 56 (ä): 102822 PMID32535547show ga Immunosuppression and immunomodulation are valuable therapeutic approaches for managing neuroimmunological diseases. In times of the Coronavirus disease 2019 (COVID-19) pandemic, clinicians must deal with the question of whether immunotherapy should currently be initiated or discontinued in neurological patients. Uncertainty exists especially because different national medical associations publish different recommendations on the extent to which immunotherapies must be continued, monitored, or possibly switched during the current pandemic. Based on the most recently available data both about the novel coronavirus and the approved immunotherapies for neurological diseases, we provide an updated overview that includes current treatment strategies and the associated COVID-19 risk, but also the potential of immunotherapies to treat COVID-19. |*Immunotherapy[MESH] |Antibodies, Monoclonal/therapeutic use[MESH] |Betacoronavirus/isolation & purification/physiology[MESH] |COVID-19[MESH] |Complement System Proteins/metabolism[MESH] |Coronavirus Infections/complications/*pathology/virology[MESH] |Humans[MESH] |Immunity, Active[MESH] |Immunosuppressive Agents/therapeutic use[MESH] |Nervous System Diseases/complications/*therapy[MESH] |Pandemics[MESH] |Pneumonia, Viral/complications/*pathology/virology[MESH] |SARS-CoV-2[MESH]Merits and culprits of immunotherapies for neurological diseases in ti(epmc).pdf DeepDyve Pubget Overpricing